Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.
Karakas M, Friede T, Butler J, Talha KM, Placzek M, Asendorf T, Diek M, Nosko A, Stas A, Kluge S, Jarczak D, DeHeer G, Rybczynski M, Bayes-Genis A, Böhm M, Coats AJS, Edelmann F, Filippatos G, Hasenfuß G, Haverkamp W, Lainscak M, Landmesser U, Macdougall IC, Merkely B, Pieske BM, Pinto FJ, Rassaf T, Visser-Rogers JK, Rosano G, Volterrani M, von Haehling S, Anker MS, Doehner W, Ince H, Koehler F, Savarese G, Khan MS, Kröhnert UR, Gori T, Trenkwalder T, Akin I, Paitazoglou C, Kobielusz-Gembala I, Kuthi L, Frey N, Licka M, Kääb S, Laugwitz KL, Ponikowski P, Anker SD.
Karakas M, et al. Among authors: rybczynski m.
Eur J Heart Fail. 2025 Jul 31. doi: 10.1002/ejhf.3742. Online ahead of print.
Eur J Heart Fail. 2025.
PMID: 40740027